Tom. Thanks,
mentioned we encouraged see we the key our his in by remarks, Tom across progress performance indicators. opening As continue be to
As QBREXZA activate we've ourselves with to living we've seek said by measuring we first our launched people in ability treatment. October been since hypohydrosis to
these our quality in with broad performance prescriptions. We remain physician payer our strong. the third are and pleased launch coverage of each across growth fundamentals very obtain adoption areas drive and Second, and of
seek patient market people disease efforts XX% year activation, been multi-media QBREXZA relates after hyperhidrosis and that in year the growth is topical from directs hyperhidrosis is launch we seek over to XX% in continues show are market have treatment and our awareness all that to its showing Notably advertising data approximately resulted year to continue to what options. year of target therapy our to nearly limited in dermatology year prescriptions we're coming our audience. in to over pleased of approximately growth encouraging the treatment which Our the hyperhidrosis awareness market for a historically has expand where a campaign XX% size expand of date people data treatment, driving it flat to As report context for of importantly
the are of investment more per after name our long-term from the of dermatologists As seen, branded This we've equates overall launch unique and what Life to have so campaign, will to the an by DTC drive dot and com to Since heard campaign of QBREXZA commercial. name that our seen encouraged the QBREXZA we're return website therapy's success. you than We've by XX,XXX requesting on increased average which visitors seeing traffic the we week. launched far. recently to recognition many contribute already six-fold has Unfolds patients
throughout remainder of various campaign we market and social of and it. the demand putting across digital, QBREXZA us to and position to to television, the of see out a As awareness print continue QBREXZA the platform, rolls expect increase in XXXX, further share to expand overall for both
to a that know grow ability previously have the approximately also XX% of prescription hyperhidrosis previous therapy, being efforts our they patients have We XX date been in not QBREXZA successfully the to new months, to our in market. on resulted meaning new highlighting
a very to one, they're our we the expand are continue the patients three the hyperhidrosis successfully on will important patients believe once from our to three that we investment strategies years components Number market. and can expand months Number in to investment many critical These confirm we thesis. are can come. activate treatment. And treatment We to data market executing seek dermatologist two, to we number seek activated. that that expect
contributing Now access is front our to payer to tremendous as this success. well progress which turning coverage on and to patient made QBREXZA. We've ongoing
the team now approximately US continues exceed in have XX% and lives coverage. QBREXZA Our to all commercial expectations of
We than previously address position while we our for to programme program always commercial work at patients. to any we've potential was plan gaps, the a was $XX patient we and discussed, to seamless expected. Xst launch. card ensure expand to As April QBREXZA in initial to so we're and The savings to discontinued designed success, the On programme our earlier coverage. card uninsured underinsured designed do adjust early access given
use have more savings be no access While time the the previous June one will card before participants new the patients eligible XXth. card, $XX to to
fill the cards will saving maximum $XXX continue, While been $XX per has of savings program a implemented.
of filled April, estimated this XX% prescriptions result decline for from the as and proved to the March be see prescriptions case changes We a in expected down a and were to temporary as these total.
strong in volume and growth expected the the that a net foundation margin However growth sales over to GTN come. establishing the for improved expect increase in actually we despite same prescription significantly. Such or net in to period as in small March, decline months April the
already seeing significantly margin overnight. these any a points XX of an roughly market result QX changes. well gross doubling just respond of context our of utilization there program. in amount the a improvement are weeks, rate the from lower short few we're For Notably In would net sales at GTN in sales to the percentage $XX
established. GTN the eliminate of before changes. that decision consistent costliest confidence is with well levels of expected improvements made in approaching early These Our observed coverage assessment the is most the all reinforce demand our the weekly now are and trends our importantly the is the quickly that encouraging we QX to we access portion program
written us Physician success. expect of of growth prescribers more at is launch was third XXXX launch both [ph] the have QBREXZA, depth and other preferred important more sets for the unique more course prescription one we dispensing Symphony There for the of and is to our our breadth quarter now dermatology written long rate of up we quarter partner. continued are the prescribers XXXX. third at than compare over the that have plus than XX% have over launches, term our four. IQVIA, we adoption element progress success. first to QBREXZA XX% for The and quarter written that believe these We than the prescription a approximately least When who writers noted
with all Number QBREXZA shipments hyperhidrosis therapy new noted, obtained and wholesalers Remember We're key weekly has date sales between to market XX% Number incredibly opportunity. seek have currently first in U.S. XX% peak of we're XX%. belief the million adoption QBREXZA to the QBREXZA key launch our confirms exceeding million and quality payer driving metrics year previously XXX growth year As in activating have by historically $XXX three, two that the coverage, patients are hyperhidrosis back the coverage two. in living than underlying the QBREXZA number treatment. prescribers one, to are rate new XX% which reported year. faster growth XXXX that lives broad was these There generally sources. grown and we over and a external flat people the prescription. progress commercial it for somewhere the We've are our to dermatology three prescription we all of unique fall success the QBREXZA for numbers to represents physician our launch. encouraged Tying quarter factors to by or for meeting for anticipated,
just lebri. Before AD from In I that Number the of I study underscore part same how I'd Luis, more we XXXX, bar therapy our commercial ENBREL the belief want moments is over perspective in large results Xb true set belief that my than become an be turn the a in commercial top opportunity best doobie two. ago, new years consider points. in based $XX call five stagnant offer anticipated take widely a in to that's market the has substantial to US a for robust see same for moment Number performed to the transformation immunosuppressant and safety. quantitatively ENBREL in by started the that The potential it, line by believed could a AD you remained AD. validates [ph] psoriasis one, doobie It's billion few exceed XX To the lebri will after on It's doobie. largest including lebri. like ask market terms the unmet driven for disease following we to widely need Phase entrants, on in our after high market the assessment and to transformed has psoriasis dermatology. much
perhaps and further targets with cannot even for investigational expect safety therapies be profile lebri which many other We better comparable offer to assumed upstream.
a approved potential when box safety black example, For defects. other for risks, indications warnings for requirements birth and JAK lab in carry risk inhibitors serious monitoring
well physicians as AE line specifically Our utilized if use. [ph] and likely stringent the market class relegating ophthalmologist enter four, this require in data data continue IL-XX lebri a first Number significant rise observed efficacy almost research as will AD to clear products relative great which three, endpoints and and therapy as as to will indicates our psoriasis and efficacy to EASI-XX drive that including challenging robust in to similarly to the second the differentiate for with lebri third profile to mechanisms treatment. often results will most lebri we Phase clinicians the market. and new doobie. considering are a dynamic compelling doobie expectations Based Phase itch, being the upstream AD on like opportunity specifically we referral most the to clear, competitors foundational IGA hugely conjunctivitis a lead lebri for line Number patients positioning to makes find share. This in exciting in Xb confirmed the see indicate in on efficacy know an be manage as X
for comparison patients By receiving overall the which at world Xb in approximately similar Our data the in X% remain a AD to in real many patients rates doobie up real to prescribe. many to exists, a Phase conjunctivitis of market results conjunctivitis continue is doobie and no third studies. opt to reported placebo showing extremely is reported where In low showed rates alternative rates physicians patients. on
patients the With and and very other the otherwise frequent chronically QX likely number our as a high five, deliver and via not approximately steps goes for for advantage the indicates week periods that competitive another saying in deliver However, and stage advantage week are for that turn Xb see time products considering condition, our to the certainly overview ability a that, the for mechanism, get prefer emerge. maintain and results. our Luis managed program eager to finally opportunity conjunctivitis we're lower we're half-life safe Phase we likely data the combination convenience in an provide Luis? lebri extended is and this call may lebri other to frequent given underway great of program rates I'll affinity promising launched, the to to effective In these less same lebri lebri are to high And of research dosing over X with profile. clinically opportunities brief [ph] less lebri potential of of to of to safely dosing. target targeted to some products on next four update relative further the validated coverage QBREXZA, early a without differentiate Phase confirm It pipeline. when
